<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NILANDRON- nilutamide tablet </strong><br>Covis Pharmaceuticals, Inc.<br></p></div>
<h1>
<span class="Bold">NILANDRON<span class="Sup">®</span></span><br><span class="Bold">(nilutamide)</span><br><span class="Bold">Tablets</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_36372a10-22fb-446b-94ab-41fb4aee39fb"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">NILANDRON<span class="Sup">®</span> tablets contain nilutamide, a nonsteroidal, orally active antiandrogen having the chemical name 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione with the following structural formula:</p>
<div class="Figure">
<a name="id256"></a><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a682f5ef-c79f-419e-94b6-b1a84b7b6651&amp;name=e69604d9-ba3f-4714-bba2-9e8bc651edee-01.jpg">
</div>
<p>Nilutamide is a microcrystalline, white to practically white powder with a molecular weight of 317.25. </p>
<p>Its molecular formula is C<span class="Sub">12</span>H<span class="Sub">10</span>F<span class="Sub">3</span>N<span class="Sub">3</span>O<span class="Sub">4</span>.</p>
<p>It is freely soluble in ethyl acetate, acetone, chloroform, ethyl alcohol, dichloromethane, and methanol. It is slightly soluble in water [&lt;0.1% W/V at 25°C (77°F)]. It melts between 153°C and 156°C (307.4°F and 312.8°F).</p>
<p>Each NILANDRON tablet contains 150 mg of nilutamide. Other ingredients in NILANDRON tablets are corn starch, lactose, povidone, docusate sodium, magnesium stearate, and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_38220ce6-185e-4d03-87e2-ecf412e36604"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_b3cd4379-794c-4599-83f1-09cbc04b29e5"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Prostate cancer is known to be androgen sensitive and responds to androgen ablation. In animal studies, nilutamide has demonstrated antiandrogenic activity without other hormonal (estrogen, progesterone, mineralocorticoid, and glucocorticoid) effects. In vitro, nilutamide blocks the effects of testosterone at the androgen receptor level. In vivo, nilutamide interacts with the androgen receptor and prevents the normal androgenic response. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_b4299deb-73bd-4e4d-9e64-73aaf37011de"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_25da7595-2695-4430-9606-562b5886a655"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Bold">Absorption</span></h3>
<p class="First">Analysis of blood, urine, and feces samples following a single oral 150-mg dose of [<span class="Sup">14</span>C]-nilutamide in patients with metastatic prostate cancer showed that the drug is rapidly and completely absorbed and that it yields high and persistent plasma concentrations. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d157afde-49dc-4541-ab6b-747c3e9e0ec3"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">After absorption of the drug, there is a detectable distribution phase. There is moderate binding of the drug to plasma proteins and low binding to erythrocytes. The binding is nonsaturable except in the case of alpha-1-glycoprotein, which makes a minor contribution to the total concentration of proteins in the plasma. The results of binding studies do not indicate any effects that would cause nonlinear pharmacokinetics. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5037ae3-5ad3-4022-b7fa-82cc088302aa"></a><a name="section-2.2.3"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">The results of a human metabolism study using <span class="Sup">14</span>C-radiolabelled tablets show that nilutamide is extensively metabolized and less than 2% of the drug is excreted unchanged in urine after 5 days. Five metabolites have been isolated from human urine. Two metabolites display an asymmetric center, due to oxidation of a methyl group, resulting in the formation of D- and L-isomers. One of the metabolites was shown, in vitro, to possess 25 to 50% of the pharmacological activity of the parent drug, and the D-isomer of the active metabolite showed equal or greater potency compared to the L-isomer. However, the pharmacokinetics and the pharmacodynamics of the metabolites have not been fully investigated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2233a3c-6b3b-467f-8ab0-03e051a1619c"></a><a name="section-2.2.4"></a><p></p>
<h3><span class="Bold">Elimination</span></h3>
<p class="First">The majority (62%) of orally administered [<span class="Sup">14</span>C]-nilutamide is eliminated in the urine during the first 120 hours after a single 150-mg dose. Fecal elimination is negligible, ranging from 1.4% to 7% of the dose after 4 to 5 days. Excretion of radioactivity in urine likely continues beyond 5 days. The mean elimination half-life of nilutamide determined in studies in which subjects received a single dose of 100–300 mg ranged from 38.0 to 59.1 hours with most values between 41 and 49 hours. The elimination of at least one metabolite is generally longer than that of unchanged nilutamide (59–126 hours). During multiple dosing of 150 mg nilutamide (given as 3 × 50 mg) twice a day, steady state was reached within 2 to 4 weeks for most patients, and mean steady state AUC<span class="Sub">0–12</span> was 110% higher than the AUC<span class="Sub">0–∞</span>obtained from the first 150 mg dose. These data and in vitro metabolism data suggest that, upon multiple dosing, metabolic enzyme inhibition may occur for this drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_433470b7-f0fa-4236-aca3-5d5be9d04686"></a><a name="section-2.3"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">Nilutamide through its antiandrogenic activity can complement surgical castration, which suppresses only testicular <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>. The effects of the combined therapy were studied in patients with previously untreated metastatic prostate cancer.</p>
<p>In a double-blind, randomized, multicenter study that enrolled 457 patients (225 treated with orchiectomy and NILANDRON, 232 treated with orchiectomy and placebo), the NILANDRON group showed a statistically significant benefit in time to progression and time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The results are summarized below.</p>
<table width="100%">
<col width="48%">
<col width="27%">
<col width="25%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">NILANDRON</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">PLACEBO</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Median Survival (months)</p></td>
<td class="Toprule"><p class="First">27.3</p></td>
<td class="Toprule"><p class="First">23.6</p></td>
</tr>
<tr>
<td><p class="First">Progression-Free Survival (months)</p></td>
<td><p class="First">21.1</p></td>
<td><p class="First">14.9</p></td>
</tr>
<tr>
<td><p class="First">Complete or Partial Regression</p></td>
<td><p class="First">41%</p></td>
<td><p class="First">24%</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Improvement in <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone Pain</span></p></td>
<td class="Botrule"><p class="First">54%</p></td>
<td class="Botrule"><p class="First">37%</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_88bfa9c9-d29d-464b-afc9-e26177f8ff82"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_438f9c2d-fc53-4723-9fcb-67eab0d3a677"></a><a name="section-3.1"></a><p></p>
<h2>Metastatic Prostate Cancer</h2>
<p class="First">NILANDRON tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D<span class="Sub">2</span>).</p>
<p>For maximum benefit, NILANDRON treatment must begin on the same day as or on the day after surgical castration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_765e93c4-e4ff-49fc-bbb7-958ad8e09178"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">NILANDRON tablets are contraindicated:</p>
<dl>
<dt>•</dt>
<dd>in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (baseline hepatic enzymes should be evaluated prior to treatment)</dd>
<dt>•</dt>
<dd>in patients with severe <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span></dd>
<dt>•</dt>
<dd>in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to nilutamide or any component of this preparation.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_b85bb73e-cc53-4f4c-b3cf-70cf8287b871"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="id_a5aca4fa-d86e-486b-88d3-bc7638a0ac35"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Pneumonitis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial pneumonitis</span> has been reported in 2% of patients in controlled clinical trials in patients exposed to nilutamide. A small study in Japanese subjects showed that 8 of 47 patients (17%) developed <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>. Reports of interstitial changes including <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span> that led to hospitalization and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported rarely post-marketing. Symptoms included <span class="product-label-link" type="condition" conceptid="4263848" conceptname="Dyspnea on exertion">exertional dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. X-rays showed interstitial or alveolo-interstitial changes, and pulmonary function tests revealed a restrictive pattern with decreased DLco. Most cases occurred within the first 3 months of treatment with NILANDRON, and most reversed with discontinuation of therapy. A routine chest X-ray should be performed prior to initiating treatment with NILANDRON. Baseline pulmonary function tests may be considered. Patients should be instructed to report any new or worsening <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> that they experience while on NILANDRON. If symptoms occur, NILANDRON should be immediately discontinued until it can be determined if the symptoms are drug related. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4e7ba86-7950-4864-8dfa-db7bf111a3a9"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span></h2>
<p class="First">Rare cases of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization due to severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> have been reported post-marketing in association with the use of NILANDRON. Hepatotoxicity in these reports generally occurred within the first 3 to 4 months of treatment. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> or marked increases in liver enzymes leading to drug discontinuation occurred in 1% of NILANDRON patients in controlled clinical trials.</p>
<p>Serum transaminase levels should be measured prior to starting treatment with NILANDRON, at regular intervals for the first 4 months of treatment, and periodically thereafter. Liver function tests should also be obtained at the first sign or symptom suggestive of liver dysfunction, e.g. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, "flu-like" symptoms, dark urine, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>. If at any time, a patient has <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or their ALT rises above 2 times the upper limit of normal, NILANDRON should be immediately discontinued with close followup of liver function tests until resolution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3e11bdaa-b945-4c86-bb89-0695f2ae8213"></a><a name="section-5.2"></a><p></p>
<h2>Use in Women</h2>
<p class="First">NILANDRON has no indication for women, and should not be used in this population, particularly for non-serious or non-life threatening conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_137da6e0-89c9-43da-b995-f821c501f7d9"></a><a name="section-5.3"></a><p></p>
<h2>Other</h2>
<p class="First">Foreign postmarketing surveillance has revealed isolated cases of <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> in which a causal relationship with NILANDRON could not be ascertained.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_3fb17879-2dfb-4198-ae3f-a02ffab5c55a"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_350bcdd2-9c61-4498-98ed-67dba1834654"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24b3464d-9b8e-4f03-a644-78834aae84b4"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Antiandrogen Withdrawal Syndrome</span></h3>
<p class="First">Patients whose disease progresses while being treated with an antiandrogen may experience clinical improvement with discontinuation of the antiandrogen.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_8be738eb-aa8d-4c1f-aa26-0aef8c3bd0ec"></a><a name="section-6.2"></a><p></p>
<h2>Information For Patients</h2>
<p class="First">Patients should be informed that NILANDRON tablets should be started on the day of, or on the day after, surgical castration. They should also be informed that they should not interrupt their dosing of NILANDRON or stop taking this medication without consulting their physician.</p>
<p>Because of the possibility of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, patients should also be told to report immediately any <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> or aggravation of pre-existing <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p>Because of the possibility of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, patients should be told to consult with their physician should <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occur.</p>
<p>Because of the possibility of an intolerance to alcohol (facial flushes, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) following ingestion of NILANDRON, it is recommended that intake of alcoholic beverages be avoided by patients who experience this reaction. This effect has been reported in about 5% of patients treated with NILANDRON.</p>
<p> In clinical trials, 13% to 57% of patients receiving NILANDRON reported a delay in adaptation to dark, ranging from seconds to a few minutes, when passing from a lighted area to a dark area. This effect sometimes does not abate as drug treatment is continued. Patients who experience this effect should be cautioned about driving at night or through tunnels. This effect can be alleviated by the wearing of tinted glasses. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_553e9912-63aa-478e-ba02-243a8e96e77d"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">In vitro, nilutamide has been shown to inhibit the activity of liver cytochrome P-450 isoenzymes and, therefore, may reduce the metabolism of compounds requiring these systems.</p>
<p>Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level. The dosage of these drugs or others with a similar metabolism may need to be modified if they are administered concomitantly with nilutamide. For example, when vitamin K antagonists are administered concomitantly with nilutamide, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be carefully monitored and, if necessary, the dosage of vitamin K antagonists should be reduced.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_7cc65a6a-c788-43b0-bb3d-17ddb96190b8"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment Of Fertility</h2>
<p class="First">Administration of nilutamide to rats for 18 months at doses of 0, 5, 15, or 45 mg/kg/day produced benign Leydig cell tumors in 35% of the high-dose male rats (AUC exposures in high-dose rats were approximately 1–2 times human AUC exposures with therapeutic doses). The increased incidence of Leydig cell tumors is secondary to elevated luteinizing hormone (LH) concentrations resulting from loss of feedback inhibition at the pituitary. Elevated LH and testosterone concentrations are not observed in castrated men receiving NILANDRON. Nilutamide had no effect on the incidence, size, or time of onset of any spontaneous tumor in rats.</p>
<p>Nilutamide displayed no mutagenic effects in a variety of in vitro and in vivo tests (Ames test, mouse micronucleus test, and two chromosomal aberration tests).</p>
<p>In reproduction studies in rats, nilutamide had no effect on the reproductive function of males and females, and no lethal, teratogenic, or growth-suppressive effects on fetuses were found. The maximal dose at which nilutamide did not affect reproductive function in either sex or have an effect on fetuses was estimated to be 45 mg/kg orally (AUC exposures in rats approximately 1–2 times human therapeutic AUC exposures).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_3d7b4d77-fe15-4056-8488-9aa34a675460"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Pregnancy Category C; Animal reproduction studies have not been conducted with nilutamide. It is also not known whether nilutamide can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Nilutamide should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_f515a5c9-2fa4-4054-8332-9f559e0676e8"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been determined.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_146be973-e9c1-49b1-ac6e-13bf8fd86004"></a><a name="section-6.7"></a><p></p>
<h2>Animal Pharmacology and Toxicology</h2>
<p class="First">Administration of NILANDRON to beagle dogs resulted in drug-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> at dose levels that produce AUC exposures in dogs much lower than the AUC exposures of men receiving the therapeutic doses of 150 and 300 mg/day. Nilutamide-induced toxicity in dogs was cumulative with progressively lower doses producing <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when given for longer durations. Nilutamide given to dogs at 60 mg/kg/day (1–2 times human AUC exposure) for 1 month produced 100% mortality. Administration of 20 and 30 mg/kg/day nilutamide (1/2–1 times human AUC exposure) for 6 months resulted in 20% and 70% mortality in treated dogs. Administration to dogs of 3, 6, and 12 mg/kg/day nilutamide (1/10–1/2 human AUC exposure) for 1 year resulted in 8%, 33%, and 50% mortality, respectively. <span class="Bold">A "no-effect level" for nilutamide-induced mortality in dogs was not identified.</span> Pathology data from the one-year oral toxicity study suggest that the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in dogs were secondary to liver toxicity. Marked-to-massive hepatocellular <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and vacuolization were observed in affected dogs. Liver toxicity in dogs was not consistently associated with elevations of liver enzymes.</p>
<p>Administration of nilutamide to rats at a dose level of 45 mg/kg/day (AUC exposure in rats 1–2 times human therapeutic AUC exposures) for 18 months increased the incidence of lung pathology (granulomatous <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and chronic alveolitis).</p>
<p>The hepatic and pulmonary adverse effects observed in nilutamide-treated animals and men are similar to effects observed with another nitroaromatic compound, nitrofurantoin. Nilutamide and nitrofurantoin are both metabolized in vitro to nitroanion free-radicals by microsomal NADPH-cytochrome P450 reductase in the lungs and liver of rats and humans. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d7d64b94-d628-46f9-be71-5a4687eedaed"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse experiences were reported during a multicenter clinical trial comparing NILANDRON + surgical castration versus placebo + surgical castration. The most frequently reported (greater than 5%) adverse experiences during treatment with NILANDRON tablets in combination with surgical castration are listed below. For comparison, adverse experiences seen with surgical castration and placebo are also listed.</p>
<table width="100%">
<col width="48%">
<col width="28%">
<col width="25%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="bottom"><span class="Bold">Adverse Experience</span></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">NILANDRON</span><br><span class="Bold"> +</span><br><span class="Bold">surgical </span><br><span class="Bold"> castration </span><br><span class="Bold">(N=225)</span><br><span class="Bold">% All</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">+</span><br><span class="Bold">surgical</span><br><span class="Bold"> castration </span><br><span class="Bold">(N=232)</span><br><span class="Bold">% All</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Cardiovascular System</p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td><p class="First">5.3</p></td>
<td><p class="First">2.6</p></td>
</tr>
<tr>
<td><p class="First">Digestive System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td><p class="First">9.8</p></td>
<td><p class="First">6.0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td><p class="First">7.1</p></td>
<td><p class="First">3.9</p></td>
</tr>
<tr>
<td><p class="First">Endocrine System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flushes</span></p></td>
<td><p class="First">28.4</p></td>
<td><p class="First">22.4</p></td>
</tr>
<tr>
<td><p class="First">Metabolic and Nutritional System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  Increased AST</p></td>
<td><p class="First">8.0</p></td>
<td><p class="First">3.9</p></td>
</tr>
<tr>
<td><p class="First">  Increased ALT</p></td>
<td><p class="First">7.6</p></td>
<td><p class="First">4.3</p></td>
</tr>
<tr>
<td><p class="First">Nervous System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td><p class="First">7.1</p></td>
<td><p class="First">3.4</p></td>
</tr>
<tr>
<td><p class="First">Respiratory System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td><p class="First">6.2</p></td>
<td><p class="First">7.3</p></td>
</tr>
<tr>
<td><p class="First">Special Senses</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  Impaired adaptation to dark</p></td>
<td><p class="First">12.9</p></td>
<td><p class="First">1.3</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></p></td>
<td><p class="First">6.7</p></td>
<td><p class="First">1.7</p></td>
</tr>
<tr>
<td><p class="First">Urogenital System</p></td>
<td></td>
<td></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></p></td>
<td class="Botrule"><p class="First">8.0</p></td>
<td class="Botrule"><p class="First">9.1</p></td>
</tr>
</tbody>
</table>
<p>The overall incidence of adverse experiences was 86% (194/225) for the NILANDRON group and 81% (188/232) for the placebo group.</p>
<p>The following adverse experiences were reported during a multicenter clinical trial comparing NILANDRON + leuprolide versus placebo + leuprolide. The most frequently reported (greater than 5%) adverse experiences during treatment with NILANDRON tablets in combination with leuprolide are listed below. For comparison, adverse experiences seen with leuprolide and placebo are also listed.</p>
<table width="100%">
<col width="48%">
<col width="28%">
<col width="25%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="bottom"><span class="Bold">Adverse Experience</span></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">NILANDRON</span><br><span class="Bold"> +</span><br><span class="Bold">leuprolide</span><br><span class="Bold"> (N=209) </span><br><span class="Bold">% All</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold"> + </span><br><span class="Bold"> leuprolide</span><br><span class="Bold"> (N=202) </span><br><span class="Bold">% All</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Body as a Whole</p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td><p class="First">26.8</p></td>
<td><p class="First">27.7</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td><p class="First">13.9</p></td>
<td><p class="First">10.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td><p class="First">19.1</p></td>
<td><p class="First">20.8</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td><p class="First">11.5</p></td>
<td><p class="First">16.8</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td><p class="First">10.0</p></td>
<td><p class="First">5.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
<td><p class="First">7.2</p></td>
<td><p class="First">4.5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span></p></td>
<td><p class="First">7.2</p></td>
<td><p class="First">3.0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td><p class="First">5.3</p></td>
<td><p class="First">6.4</p></td>
</tr>
<tr>
<td><p class="First">Cardiovascular System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td><p class="First">9.1</p></td>
<td><p class="First">9.9</p></td>
</tr>
<tr>
<td><p class="First">Digestive System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td><p class="First">23.9</p></td>
<td><p class="First">8.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td><p class="First">19.6</p></td>
<td><p class="First">16.8</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td><p class="First">11.0</p></td>
<td><p class="First">6.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td><p class="First">6.7</p></td>
<td><p class="First">4.5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td><p class="First">5.7</p></td>
<td><p class="First">4.0</p></td>
</tr>
<tr>
<td><p class="First">Endocrine System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flushes</span></p></td>
<td><p class="First">66.5</p></td>
<td><p class="First">59.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></p></td>
<td><p class="First">11.0</p></td>
<td><p class="First">12.9</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span></p></td>
<td><p class="First">11.0</p></td>
<td><p class="First">4.5</p></td>
</tr>
<tr>
<td><p class="First">Hemic and Lymphatic System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td><p class="First">7.2</p></td>
<td><p class="First">6.4</p></td>
</tr>
<tr>
<td><p class="First">Metabolic and Nutritional System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  Increased AST</p></td>
<td><p class="First">12.9</p></td>
<td><p class="First">13.9</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></p></td>
<td><p class="First">12.4</p></td>
<td><p class="First">17.3</p></td>
</tr>
<tr>
<td><p class="First">  Increased ALT</p></td>
<td><p class="First">9.1</p></td>
<td><p class="First">8.9</p></td>
</tr>
<tr>
<td><p class="First">Musculoskeletal System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone Pain</span></p></td>
<td><p class="First">6.2</p></td>
<td><p class="First">5.0</p></td>
</tr>
<tr>
<td><p class="First">Nervous System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td><p class="First">16.3</p></td>
<td><p class="First">15.8</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td><p class="First">10.0</p></td>
<td><p class="First">11.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td><p class="First">8.6</p></td>
<td><p class="First">7.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypesthesia</span></p></td>
<td><p class="First">5.3</p></td>
<td><p class="First">2.0</p></td>
</tr>
<tr>
<td><p class="First">Respiratory System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td><p class="First">10.5</p></td>
<td><p class="First">7.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infection</span></p></td>
<td><p class="First">8.1</p></td>
<td><p class="First">10.9</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td><p class="First">5.3</p></td>
<td><p class="First">3.5</p></td>
</tr>
<tr>
<td><p class="First">Skin and Appendages</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td><p class="First">6.2</p></td>
<td><p class="First">3.0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Body hair loss</span></p></td>
<td><p class="First">5.7</p></td>
<td><p class="First">0.5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></p></td>
<td><p class="First">5.3</p></td>
<td><p class="First">2.5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td><p class="First">5.3</p></td>
<td><p class="First">4.0</p></td>
</tr>
<tr>
<td><p class="First">Special Senses</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  Impaired adaptation to dark</p></td>
<td><p class="First">56.9</p></td>
<td><p class="First">5.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">Chromatopsia</span></p></td>
<td><p class="First">8.6</p></td>
<td><p class="First">0.0</p></td>
</tr>
<tr>
<td><p class="First">  Impaired adaptation to light</p></td>
<td><p class="First">7.7</p></td>
<td><p class="First">1.0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></p></td>
<td><p class="First">6.2</p></td>
<td><p class="First">4.5</p></td>
</tr>
<tr>
<td><p class="First">Urogenital System</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">Testicular atrophy</span></p></td>
<td><p class="First">16.3</p></td>
<td><p class="First">12.4</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span></p></td>
<td><p class="First">10.5</p></td>
<td><p class="First">11.9</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></p></td>
<td><p class="First">8.6</p></td>
<td><p class="First">21.3</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p></td>
<td><p class="First">8.1</p></td>
<td><p class="First">7.9</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="197331" conceptname="Disorder of urinary tract">Urinary tract disorder</span></p></td>
<td><p class="First">7.2</p></td>
<td><p class="First">10.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">Nocturia</span></p></td>
<td class="Botrule"><p class="First">6.7</p></td>
<td class="Botrule"><p class="First">6.4</p></td>
</tr>
</tbody>
</table>
<p>The overall incidence of adverse experiences is 99.5% (208/209) for the NILANDRON group and 98.5% (199/202) for the placebo group.</p>
<p>Some frequently occurring adverse experiences, for example <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and decreased libido, are known to be associated with low serum androgen levels and known to occur with medical or surgical castration alone. Notable was the higher incidence of <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (variously described as impaired adaptation to darkness, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, and colored vision), which led to treatment discontinuation in 1% to 2% of patients. </p>
<p><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial pneumonitis</span> occurred in one (&lt;1%) patient receiving NILANDRON in combination with surgical castration and in seven patients (3%) receiving NILANDRON in combination with leuprolide and one patient receiving placebo in combination with leuprolide. Overall, it has been reported in 2% of patients receiving NILANDRON. This included a report of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> in 8 of 47 patients (17%) in a small study performed in Japan.</p>
<p>In addition, the following adverse experiences were reported in 2 to 5% of patients treated with NILANDRON in combination with leuprolide or orchiectomy.</p>
<p> Body as a Whole: <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> (2%).</p>
<p> Cardiovascular System: Angina (2%), <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (3%), <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (2%).</p>
<p> Digestive System: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (2%), <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span> (2%), <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (2%), <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span> (2%).</p>
<p> Metabolic and Nutritional System: <span class="product-label-link" type="condition" conceptid="4010023" conceptname="Alcohol intolerance">Alcohol intolerance</span> (5%), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (2%), <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> (2%).</p>
<p> Musculoskeletal System: <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> (2%).</p>
<p> Nervous System: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span> (2%), <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> (2%), <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (3%).</p>
<p> Respiratory System: <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span> (2%), <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> (2%), <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorder</span> (4%), <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (2%).</p>
<p> Skin and Appendages: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> (2%).</p>
<p> Special Senses: <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract</span> (2%), <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> (2%).</p>
<p> Laboratory Values: Haptoglobin increased (2%), <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (3%), alkaline phosphatase increased (3%), BUN increased (2%), creatinine increased (2%), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (4%).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_622c7b01-55a7-4f32-96d7-e27bbbc6a8b5"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">One case of massive overdosage has been published. A 79-year-old man <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span> by ingesting 13 g of nilutamide (i.e., 43 times the maximum recommended dose). Despite immediate gastric lavage and oral administration of activated charcoal, plasma nilutamide levels peaked at 6 times the normal range 2 hours after ingestion. There were no clinical signs or symptoms or changes in parameters such as transaminases or chest X-ray. Maintenance treatment (150 mg/day) was resumed 30 days later.</p>
<p>In repeated-dose tolerance studies, doses of 600 mg/day and 900 mg/day were administered to 9 and 4 patients, respectively. The ingestion of these doses was associated with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. In addition, a transient elevation in hepatic enzyme levels was noted in one patient. </p>
<p>Since nilutamide is protein bound, dialysis may not be useful as treatment for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken. If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> does not occur spontaneously, it should be induced if the patient is alert. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_7d09dcf7-4555-4493-b2d0-3bcbd6389c74"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dosage is 300 mg once a day for 30 days, followed thereafter by 150 mg once a day. NILANDRON tablets can be taken with or without food.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_7c2e25e5-11ef-40c4-aa89-d69e50fb7ce7"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NILANDRON 150 mg tablets are supplied in boxes of 30 tablets. Each box contains 3 child-resistant, PVC, aluminum foil-backed <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> of 10 tablets (NDC 24987-111-14). Each white, biconvex, cylindrical (10 mm in diameter) tablet has a triangular logo on one side and an internal reference number (168D) on the other. </p>
<p>Store at 25°C (77°F); excursions permitted between 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Protect from light.</p>
<p>Revised May 2013</p>
<p>Distributed by<br>Covis Pharmaceuticals, Inc. <br>Cary, NC 27511</p>
<p>Country of Origin: France</p>
<p>© 2013 Covis Pharmaceuticals, Inc.  All rights reserved.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_354ff348-3964-4487-ac0d-03e6b26c1fdd"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 24987-111-14</p>
<p><span class="Bold">Nilandron<span class="Sup">®</span>         150 </span>mg<br>nilutamide <br><span class="Bold">Tablets</span></p>
<p><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id919"></a><img alt="carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a682f5ef-c79f-419e-94b6-b1a84b7b6651&amp;name=e69604d9-ba3f-4714-bba2-9e8bc651edee-03.jpg">
</div>
<p>Carton Label</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NILANDRON 		
					</strong><br><span class="contentTableReg">nilutamide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24987-111</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Nilutamide</strong> (Nilutamide) </td>
<td class="formItem">Nilutamide</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DOCUSATE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Cylindrical) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">168D</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24987-111-14</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020169</td>
<td class="formItem">07/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Covis Pharmaceuticals, Inc.
							(969968986)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>42dc25a5-1b10-4e46-aaec-91b78d75da08</div>
<div>Set id: a682f5ef-c79f-419e-94b6-b1a84b7b6651</div>
<div>Version: 3</div>
<div>Effective Time: 20140627</div>
</div>
</div> <div class="DistributorName">Covis Pharmaceuticals, Inc.</div></p>
</body></html>
